Explain this page
Arphra AIPlain-English read on Becton, Dickinson and Company’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$364.19
+140.93% vs spot
Recommendation
Strong Buy
18 of 19 methods
Method spread
7bull7bear
±5% threshold
Analyst PT consensus: $172.85 (+14.35%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.07% | +3.43% | -1.37% | -9.55% | -0.87% | -0.92% | +11.46% | -23.77% | -17.73% | +16.88% | +553.81% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$712.2K
10 txns
Net flow
−$712.2K
Aftermarket
LiveLast trade
$150.24
Bid
$149.28
1 sh
Ask
$151.50
50 sh
Spread
$2.220
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Dec 2025 | $5.25B | $382M | $1.34 |
| Q4 Sep 2025 | $5.89B | $493M | $1.72 |
| Q3 Jun 2025 | $5.51B | $574M | $2.00 |
| Q2 Mar 2025 | $5.27B | $308M | $1.07 |
| Q1 Dec 2024 | $5.17B | $303M | $1.04 |
| Q4 Sep 2024 | $5.44B | $400M | $1.45 |
Analyst view
DB · price_targets + analyst_gradesConsensus target
$172.85
+14.35% upside
Low
$159.00
Median
$168.01
High
$202.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·May 12, 2026
- BD Appoints Vitor Roque Chief Financial Officerprnewswire.com·May 07, 2026
- BD Reports Second Quarter Fiscal 2026 Financial Resultsprnewswire.com·May 07, 2026
- Can Sustained Product Momentum Drive BDX Stock Before Q2 Earnings?zacks.com·May 04, 2026
Peers
Total assets
$55.33B
Total debt
$19.18B
Cash & equiv
$851M
Operating CF
$3.43B
Free cash flow
$2.67B
Buybacks
-$1B
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Feld Michael officer: EVP, Chief Revenue Officer | Sell | 74 | $11.24K | Apr 27, 2026 |
Feld Michael officer: EVP, Chief Revenue Officer | Sell | 75 | $11.76K | Mar 26, 2026 |
Feld Michael officer: EVP, Chief Revenue Officer | Sell | 75 | $13.64K | Feb 26, 2026 |
SCOTT BERTRAM L director | Sell | 953 | $174.03K | Feb 18, 2026 |
Feld Michael officer: EVP, CRO & Pres. Life Sciences | Sell | 75 | $15.2K | Jan 26, 2026 |
Garrison Michael David officer: EVP & Pres Med.Essntl&BioPharm | Sell | 1,010 | $208.61K | Jan 15, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $21.84B | $2.58B | $1.68B | $5.83 | +7.68% |
| FY 2024 | $20.18B | $2.4B | $1.71B | $5.86 | +8.45% |
| FY 2023 | $19.37B | $2.11B | $1.48B | $4.94 | +7.66% |
| FY 2022 | $18.87B | $2.28B | $1.78B | $5.88 | +9.43% |
| FY 2021 | $19.13B | $2.25B | $2.09B | $6.85 | +10.94% |